The Swiss pharmaceutical giant Roche said it had reached a sublicensing deal for production of its flagship anti-influenza drug Tamiflu in China with Shanghai Pharmaceutical group. Roche said in a statement that it had identified a total of 12 potential partners for production of the drug, which is regarded as a first line of treatment for bird flu.
